Abstracts Archive - Page 791 of 2607 - ACR Meeting Abstracts

Abstract Number: 1288 • ACR Convergence 2021
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Mia Rodziewicz¹, Sarah Dyball¹, Stephen McDonald¹, Emily Sutton¹, Ben Parker¹, The British Isles Lupus Assessment Group² and Ian N. Bruce¹, ¹University of Manchester, Manchester, United Kingdom, ²Lupus Trust, London
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of infection compared to the general population. We aimed to assess the early risk…
Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Philip Carlucci¹, Jessica Li², Heather Gold³, Kristina Deonaraine¹, Andrea Fava², Jill Buyon⁴, Judith James⁵, Chaim Putterman⁶, Deepak Rao⁷, Betty Diamond⁸, Derek Fine², Jose Monroy-Trujillo², Kristin Haag⁹, Accelerating Medicines Partership (AMP) RA/SLE Network¹⁰, H. Michael Belmont⁴, Sean Connery¹¹, Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Parternship In SLE Network¹⁹, Peter Izmirly¹ and Michelle Petri²⁰, ¹New York University School of Medicine, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Northwell Health, Manhasset, NY, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰Brigham and Women's Hospital, Everett, MA, ¹¹Texas Tech University Health Sciences Center, Texas, TX, ¹²Texas Tech University Health Sciences Center, El Paso, TX, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵University of California San Francisco, Corte Madera, CA, ¹⁶University of California San Francisco, San Francisco, CA, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…
Abstract Number: 1290 • ACR Convergence 2021
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials
Michal Abrahamowicz¹ and Peter Lipsky², ¹McGill University, Montréal, QC, Canada, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of effective new Systemic Lupus Erythematosus (SLE) treatments requires a validated responder index responsive to clinically meaningful change and relevant to clinical practice.…
Abstract Number: 1291 • ACR Convergence 2021
Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
Eun Song Kang¹, Ji Seon Oh², Soo Min Ahn¹, Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo³ and Seokchan Hong³, ¹Asan Medical Center, Seoul, Republic of Korea, ²Asan Medical Center, Ulsan, Republic of Korea, ³Asan Medical Center, Seoul, South Korea
Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of…
Abstract Number: 1292 • ACR Convergence 2021
Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
Ehizogie Edigin¹, Precious Eseaton², Chinenye Osuorji³, Ajayi Temitope⁴, Oluwafeyi Adedoyin⁵, Nneka Chukwu⁶ and Augustine Manadan⁷, ¹Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin, Benin, Nigeria, ³Internal Medicine, Burrell College of Osteopathic Medicine, Las Cruces, NM, ⁴Internal Medicine, University of Buffalo, Buffalo, NY, ⁵Internal Medicine, Englewood Hospital and Medicine Center, Englewood, NJ, ⁶Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Longitudinal data on trends of Systemic Lupus Erythematous (SLE) readmissions is scarce. Our study aims to study trends of 30-day readmissions of patients admitted…
Abstract Number: 1293 • ACR Convergence 2021
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
Ambika Gupta¹, Sindhu Johnson², Jiandong Su³, Kathleen Bingham⁴, Andrea Knight⁵, Juan Diaz-Martinez⁶, Mahta Kakvan³, Maria Tartaglia³, Lesley Ruttan⁴, Joan Wither³, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla³, Dorcas Beaton⁹, Patricia Katz¹⁰, Robin Green³ and Zahi Touma¹, ¹University of Toronto, Mississauga, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶UHN, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a high prevalence of cognitive impairment (CI) (38% (95% confidence interval: 33-43%)). Patient reported outcomes (PROs) capture patient perceptions…
Abstract Number: 1294 • ACR Convergence 2021
Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium
Trixy David¹, Li Su², Yafeng Cheng², Caroline Gordon³, Benjamin Parker¹, David Isenberg⁴, John A Reynolds⁵ and Ian N Bruce⁶, ¹The Kellgren Centre for Rheumatology, and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Centre for Rheumatology, University College London, London, United Kingdom, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, and Rheumatology Department, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom, ⁶The Kellgren Centre for Rheumatology; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, and Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Several novel SLE therapies are in development. Precision medicine aims to improve treatment practices and real-world outcomes. Certain factors, however, will likely reflect overall…
Abstract Number: 1295 • ACR Convergence 2021
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
Michelle Petri¹, Norma Lynn Fox², Mathew Gibb³, Tania Gonzalez-Rivera², Anne Hammer², Holly Quasny⁴, Ronald van Vollenhoven⁵ and David Roth², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²GlaxoSmithKline, Collegeville, PA, ³Veramed Ltd., Twickenham, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, NC, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Belimumab (BEL) is a disease-modifying systemic lupus erythematosus (SLE) treatment that inhibits B-lymphocyte stimulator. BEL has demonstrated a consistent efficacy profile across 4 pivotal…
Abstract Number: 1296 • ACR Convergence 2021
Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study
Maria Constanza Bertolaccini¹, Yessika Soria Curi², Luciana Gonzalez Lucero³, Gabriela Vanesa Espasa², Ana Lucia Barbaglia², Hector Raul Sueldo², Maria Lilia Leguizamon², Susana Marcela Mazza², Mirta Santana², Liliana Maria Galindo², Rodrigo Aguila Maldonado⁴, Mercedes Garcia⁵, Dafne Capelusnik⁶, Ivana Romina Rojas Tessel⁷, Eugenia Picco⁷, Maria Elena Crespo Espindola⁷, Romina Calvo⁸, Susana Roverano⁹, Micaela Ana Cosatti⁹, Cecilia Nora Pisoni⁹, Paola Andrea Avila¹⁰, Marina Micelli¹¹, Maria Hu¹², Lucia Alascio¹³, Maria Cecilia Goizueta¹⁴ and Veronica Ines Bellomio², ¹Hospital Padilla, San Miguel de Tucumán, Argentina, ²Hospital Padilla, Tucuman, Argentina, ³Janssen Cilag Farmaceutica SA, Tucuman, Argentina, ⁴HIGA San Martin La Plata, La Plata, Argentina, ⁵Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Hospital Señor del Milagro, Salta, Argentina, ⁸Hospital José María Cullen, Santa Fe, Argentina, ⁹CEMIC, Buenos Aires, Argentina, ¹⁰Hospital Ramos Mejía, Buenos Aires, Argentina, ¹¹Hospital General de Agudos, Ramos Mejía - CF, Buenos Aires, Argentina, ¹²Hospital José Maria Penna, Buenos Aires, Argentina, ¹³Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ¹⁴Sanatorio 9 de Julio, Tucuman, Argentina
Background/Purpose: The mortality in lupus patients is 2–3 times higher than the general population. However, survival in these patients has improved significantly and it is…
Abstract Number: 1297 • ACR Convergence 2021
Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study
Connor Maddock¹, Behdin Nowrouzi-Kia², Jiandong Su³ and Zahi Touma⁴, ¹University College Dublin, Dublin, Ireland, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Mississauga, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems and can vary in its manifestations between individuals. SLE…
Abstract Number: 1298 • ACR Convergence 2021
Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
Martha Rodriguez¹, Kiana Rachele Johnson² and Kathleen O'Neil¹, ¹Riley Hospital for Children at Indiana University, Indianapolis, IN, ²East Tennessee state University, Johnson, TN
Background/Purpose: Pediatric Onset SLE is associated with higher disease activity and higher risk of damage. There is limited information on prepubertal patients with SLE and…
Abstract Number: 1299 • ACR Convergence 2021
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
Peter Izmirly¹, Maria Dall'Era², Kenneth Kalunian³, Kristina Deonaraine¹, Mimi Kim⁴, Philip Carlucci¹, Jessica Li⁵, Andrea Fava⁵, H. Michael Belmont⁶, Chaim Putterman⁷, Jennifer Anolik⁸, Betty Diamond⁹, David Wofsy¹⁰, Diane Kamen¹¹, Judith James¹², Accelerating Medicines Partership (AMP) RA/SLE Network¹³, Deepak Rao¹⁴, The Accelerating Medicines Partnership in SLE Network¹⁵, Michelle Petri¹⁶, Jill Buyon⁶ and Richard Furie¹⁷, ¹New York University School of Medicine, New York, NY, ²University of California San Francisco, Corte Madera, CA, ³UC San Diego, La Jolla, CA, ⁴Albert Einstein College of Medicine, Larchmont, NY, ⁵Johns Hopkins University, Baltimore, MD, ⁶NYU School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Bronx, NY, ⁸University of Rochester Medical Center, Rochester, NY, ⁹Northwell Health, Manhasset, NY, ¹⁰University of California San Francisco, San Francisco, CA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Brigham and Women's Hospital, Everett, MA, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵Multiple Institutions, Multiple Cities, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
Abstract Number: 1300 • ACR Convergence 2021
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Hamilton, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada
Background/Purpose: We have previously shown that prolonged clinical remission for ≥10 years is associated with significantly less damage accrual in inception patients with systemic lupus…
Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…
Abstract Number: 1302 • ACR Convergence 2021
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh¹, Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes Garcia¹¹, Ignacio Garcia-De La Torre¹², Regina Kurrasch¹³, Sofia Fernandes¹⁴, Julia Harris¹⁵, Saima Muzaffar¹⁴, Norma Lynn Fox¹³, Andrew Liu¹⁶, Holly Quasny¹⁷ and David Roth¹³, ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Henry Ford Hospital, Wayne State University, Detroit, MI, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ¹³GlaxoSmithKline, Collegeville, PA, ¹⁴GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ¹⁵GlaxoSmithKline, Uxbridge, United Kingdom, ¹⁶GlaxoSmithKline, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].